HNGE — Hinge Health | Earnings Review Q4 FY25 (Dec-25)

Date: 2026-02-22 Quarter: Q4 FY25 (ending December 2025) Task: Earnings Review Market Cap: ~$3.3B | EV/TTM Rev: 5.6x

The Headline

Oh man. Where to start with a company I'm coming to fresh with zero prior notes.

Q4 FY25 was Hinge Health's third quarter as a public company (IPO'd May 2025 at $32/share), and they absolutely throttled expectations. $170.7M revenue vs. $157M consensus — an 8.7% beat. Non-GAAP EPS of $0.49 vs. $0.14 expected. That's a 250% EPS beat. In their third public quarter.

I keep saying the "Is" vs "Could Be" framework is the most important question I ask about any company. Hinge Health is very clearly an "Is" company. They're not asking me to imagine a future. They're showing me one.

Q4 FY25 Results

FY25 Full Year: $587.9M revenue (+51% YoY), $117M operating income (20% margin), $179.6M FCF.

Key KPIs

The billings-to-revenue ratio is 1.14x — meaning future revenue is already contracted and not yet recognized. That's a bullish leading indicator.

The "Is" vs "Could Be" Test

Is delivering:

• 85% gross margins. That's world-class for any software company, let alone healthcare.
• 28% non-GAAP operating margin in Q4 after being deeply unprofitable a year ago.
• 97% client retention and 100% partner retention, every quarter.
• NDR above 110%, meaning existing clients are spending more each year.
• Non-ASO lives up 130% — the new growth vector is already moving.
• 47% more members with flat care team costs. Robin AI is doing real work.

Could Be (watch carefully):

• HingeSelect network (the physical PT provider network, 85% conservative care adoption) — real clinical traction but economics at scale still being proven.
• Non-ASO segment (Medicare, FEP, ACA) — 2.6M lives is early. These populations behave differently than commercial ASO. Yield and margin profile TBD.
• 21 peer-reviewed studies supporting outcomes — impressive, but does this translate to competitive moat against Sword Health?

Here's how I'm thinking about it: the core business is absolutely "Is." The expansion vectors are "Could Be" — but they're growing fast enough that I'm watching them get promoted.

The Profitability Inflection — This is the Story

The 250% EPS beat is the headline that deserves more attention than it's getting.

Management specifically called out: "47% more members while holding care team costs flat." That's Robin AI (their proprietary care delivery AI, 92% member satisfaction rating) driving operating leverage in real time. This isn't theoretical — it's showing up in the margins.

Gross margins went from ~62% three years ago to 85% today. Operating margins went from deeply negative to +28% in a single fiscal year. FCF margin is 36% and they generated $179.6M in free cash flow for the full year.

For context on how unusual this is: most digital health companies are still burning cash at scale. Hinge Health is 12 years old, but only 3 quarters public, and they're already running a Rule of 40 of 81. That's an elite number.

The Growth Deceleration Question

I won't pretend it's not there. Revenue growth trajectory:

• Q2 FY25: 55% YoY
• Q3 FY25: 53% YoY
• Q4 FY25: 46% YoY
• FY26 Guide midpoint: 25% YoY

That's a meaningful step-down from 51% (FY25) to 25% (FY26 guided). The "one more quarter" trap is real, and I've been burned before assuming deceleration stops.

But here's what makes me more comfortable than usual:

1. Billings are running at $671M TTM at 44% growth — ahead of the $737M revenue guide. They're guiding to collect what's already contracted plus some new business. This feels conservative.

2. Q1'26 guidance is $172M at 39% YoY growth — they're starting FY26 at 39% and guiding the full year at 25%. Either Q1 is the seasonal high and the back half slows dramatically, or the full-year number gets raised. Given Q4 FY25 revenue was $170.7M and they're guiding Q1 FY26 to $172M, that's basically flat sequentially — very conservative for a company with 97% retention and expanding billings.

3. Non-ASO at 130% growth — this is a new growth driver that wasn't contributing meaningfully to FY25. If it scales, it becomes a tailwind that their conservative model doesn't fully capture.

I'm not blind to the deceleration. But this looks more like deliberate sandbagging by a newly public management team than genuine deterioration. First-time public company. They crushed their first three quarters. They want to set expectations they can beat and raise. That's rational behavior.

Still watching it. Won't declare victory on one year of public track record.

FY26 Guidance

Q1 FY26: $172M revenue (+39% YoY), 18% OpM.

The margin expansion story continues — 21% target for FY26 vs 20% in FY25. Not dramatic, but they're already past the profitability inflection. Now it's about compounding.

Valuation Context

At ~$3.3B market cap and ~5.6x EV/TTM revenue, Hinge Health is cheap for what it is. I don't do DCFs and I try not to get too cute with P/S ratios, but:

• 85% gross margins
• 28% operating margins (and expanding)
• 36% FCF margins
• 110%+ NDR
• 97% client retention
• Growing at 46% YoY in Q4

Most software companies with this profile trade at 10-15x revenue. Even if you haircut for the growth deceleration, 5-7x feels right, not 5.6x. The market is pricing this like a decelerating mid-growth SaaS company, not a high-efficiency, clinically differentiated, digital health platform in a $60B market.

The $665M buyback authorization in Q4 (relative to a $3.3B market cap) is management's way of saying: "We think we're cheap." I tend to agree with them.

Prior Beliefs vs. Updated Beliefs

Prior: No prior Joe notes on HNGE. Coming in fresh.

Updated after Q4 FY25:

• This is an "Is" company operating at an elite level across every metric I track.
• Robin AI is real and the operating leverage is measurable — not theoretical.
• Management is executing with discipline in their first year as a public company. Three consecutive beats, each time raising guidance.
• The FY26 deceleration is real but appears sandbagged based on billings trajectory.
• Valuation is genuinely cheap for the profile. Under-covered as a recent IPO.
• Non-ASO (Medicare/FEP) is an emerging growth driver worth watching.

Team Roster Assessment

Position: New addition — evaluating for the roster.

Given what I'm seeing here, the question is starter or tryout. Normally for a company I'm coming to fresh with limited public track record, I'd start with a tryout (2-5%). But the combination of:

• 85% gross margins
• Already profitable with 28% OpM
• Elite retention and NDR
• Beat-and-raise pattern (3 consecutive quarters)
• Genuinely cheap valuation at 5.6x TTM revenue

...makes me want to take this more seriously than a typical tryout. If I were building this portfolio from scratch, I'd probably go starter-sized from the beginning. But with only 3 public quarters of data, I'd start at tryout size and move to starter if FY26 guidance raises confirm the sandbagging thesis.

Recommendation: Tryout (2-5%), with a clear path to starter if Q1 FY26 and Q2 FY26 beat-and-raise.

What I'm Watching

1. FY26 guidance raise cadence — first raise should come Q1 FY26. If they beat $172M and raise the full year, that's the confirmation I need.
2. Non-ASO yield and margin — do these lives generate comparable economics to commercial ASO? Management mentioned engagement-based pricing; need to see the yield data.
3. HingeSelect at scale — can they generate fee revenue from the provider network? This is a platform optionality play.
4. Sword Health IPO — private competitor with ~10M lives. Their public debut would create a direct comparison point and potentially competitive pressure.
5. Annual yield expansion — moved from 340% to 390% this year. If it continues expanding, that's organic revenue growth from existing clients, compounding on top of new client adds.

Summary

Hinge Health put up an exceptional first full year as a public company. The EPS beat of 250% in Q4 is the headline; the operating leverage story behind it is the thesis. Robin AI enabling 47% member growth with flat care team costs is the kind of efficiency inflection that compounds.

The growth deceleration from 51% to 25% guided is real and deserves respect. But billings are running ahead of the revenue guide, client retention is 97%, and Q1 guidance implies 39% growth to start the year. This feels like conservative management from a team that wants to beat expectations, not genuine deterioration.

At 5.6x TTM revenue for a company with 85% gross margins, 28% operating margins, and NDR above 110%, I think the market is mispricing this. The post-IPO under-coverage is creating an opportunity.

Tryout position to start. Watching for the FY26 beat-and-raise sequence to earn starter status.

As usual, thanks for reading.

Data Table (12 Quarters)

| | Q124 | Q224 | Q324 | Q424 | Q125 | Q225 | Q325 | Q425 | | | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 | |---|---|---|---|---|---|---|---|---| | Revenue ($M) | 89.6 | 99.0 | 109.5 | 117.0 | 125.9 | 141.0 | 150.4 | 170.7 | | YoY % | — | — | — | — | +40% | +42% | +37% | +46% | | GM [Non-GAAP] | — | — | — | 77% | — | 82% | 84% | 85% | | OpM [Non-GAAP] | — | — | — | — | — | — | — | +28% | | FCF ($M) | — | — | 25.0 | — | — | 50.7 | 47.0 | 61.5 | | FCF Margin | — | — | 22.8% | — | — | 35.9% | 31.2% | 36.0% | | TTM Billings ($M) | — | — | — | 467.5 | — | — | — | 671.4 | | Clients | 2,256 | — | — | — | — | — | 2,743 | 2,830 | | Members (K) | 532 | — | — | — | — | — | 742 | 783 | | Contracted Lives (M) | 20.0 | — | — | — | — | — | 24.1 | 24.6 |

Sources: Scout brief 2026-02-21, company IR, Motley Fool transcript.